CN110384240A - Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application - Google Patents
Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application Download PDFInfo
- Publication number
- CN110384240A CN110384240A CN201910708111.0A CN201910708111A CN110384240A CN 110384240 A CN110384240 A CN 110384240A CN 201910708111 A CN201910708111 A CN 201910708111A CN 110384240 A CN110384240 A CN 110384240A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- hypoglycemic
- probiotics fermention
- alimentation composition
- object powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011782 vitamin Substances 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000006041 probiotic Substances 0.000 title claims abstract description 26
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 26
- 229940088594 vitamin Drugs 0.000 title claims abstract description 25
- 229930003231 vitamin Natural products 0.000 title claims abstract description 25
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 25
- 150000003722 vitamin derivatives Chemical class 0.000 title claims abstract description 24
- 239000000843 powder Substances 0.000 title claims abstract description 23
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 21
- 239000008280 blood Substances 0.000 claims abstract description 20
- 239000011812 mixed powder Substances 0.000 claims abstract description 8
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 20
- 239000011719 vitamin A Substances 0.000 claims description 20
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 19
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 19
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 19
- 229940045997 vitamin a Drugs 0.000 claims description 19
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 17
- 229960002079 calcium pantothenate Drugs 0.000 claims description 17
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 15
- 229930003571 Vitamin B5 Natural products 0.000 claims description 15
- 235000009492 vitamin B5 Nutrition 0.000 claims description 15
- 239000011675 vitamin B5 Substances 0.000 claims description 15
- 229930003779 Vitamin B12 Natural products 0.000 claims description 13
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 13
- 239000011715 vitamin B12 Substances 0.000 claims description 13
- 235000019163 vitamin B12 Nutrition 0.000 claims description 13
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 9
- 235000013734 beta-carotene Nutrition 0.000 claims description 9
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 9
- 239000011648 beta-carotene Substances 0.000 claims description 9
- 229960002747 betacarotene Drugs 0.000 claims description 9
- 229960000342 retinol acetate Drugs 0.000 claims description 9
- 235000019173 retinyl acetate Nutrition 0.000 claims description 9
- 239000011770 retinyl acetate Substances 0.000 claims description 9
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 9
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960002061 ergocalciferol Drugs 0.000 claims description 2
- 239000011653 vitamin D2 Substances 0.000 claims description 2
- 235000001892 vitamin D2 Nutrition 0.000 claims description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 230000036039 immunity Effects 0.000 abstract description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 2
- 206010034960 Photophobia Diseases 0.000 abstract description 2
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000004300 dark adaptation Effects 0.000 abstract description 2
- 210000001508 eye Anatomy 0.000 abstract description 2
- 208000030533 eye disease Diseases 0.000 abstract description 2
- 210000004211 gastric acid Anatomy 0.000 abstract description 2
- 210000003128 head Anatomy 0.000 abstract description 2
- 208000002780 macular degeneration Diseases 0.000 abstract description 2
- 208000001491 myopia Diseases 0.000 abstract description 2
- 230000004379 myopia Effects 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000008103 glucose Substances 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- -1 ablastins Chemical class 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000254223 Syntexis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application, the component including parts by weight: 10 parts~15 parts of vitamin mixed powder, 1~5 part of probiotics fermention object powder, 0.5 part~70 parts of sugar alcohol.The present invention is safe and healthy, can enter blood by buccal absorption in Orally disintegrating, head cross answer it is small, it is rapid-action, also reduce destruction of the gastric acid to the alimentation composition, improve bioavilability.The composition, which also has, prevents and treats the eye diseases such as dry and astringent weak ophthalmodynia, dark adaptation, eye-blurred, photophobia, eyes, blink, myopia or macular degeneration, also has anti-aging, anti-inflammatory, the effect for improving immunity.
Description
Technical field
The present invention relates to a kind of hypoglycemic alimentation compositions.
Background technique
Diabetes are the universally acknowledged diseases for being difficult to cure, and are by inherent cause, immunologic function disorder, microorganism infection
And its various virulence factors of toxin, free radical toxin, mental element etc. act on body and lead to hypoinsulinism, insulin
A series of metabolic disorder syndromes such as sugar, protein, fat, water and electrolyte of resistance etc. and initiation, clinically with hyperglycemia
For main feature, typical patient may occur in which the performances, i.e. " three-many-one-little " symptom such as diuresis, more drinks, more food, syntexis.
Diabetes can cause multiple complications.If diabetes do not obtain enough control, some urgency can be caused
Property complication, as hypoglycemia, ketoacidosis, non-ketone hyperosmolar coma, glucose -lipid metabolism disorder and inhereditary material stability drop
It is low.Serious long-term complications include: cardiovascular disease, (also known as diabetic nephropathy is that developing country is non-for chronic renal failure
The principal disease of aged adult's blinding), neuropathy and microangiopathies.Wherein, microangiopathies may cause erection function
Energy obstacle (impotence) and wound are difficult to heal.And foot is difficult to the wound to heal then and may cause gangrene and (is commonly called as " diabetes
Foot "), and then lead to patient's amputation.
Currently, the drug for treating diabetes is various, type has Chinese medicine class, western medicine class, the medicine of these treatment diabetes
Object has certain curative effect, but haves the defects that certain: western medicine class has certain side effect, such as melbine, can be quickly after intake
Blood glucose is reduced, control is bad to easily lead to hypoglycemia;Chinese medicine class treatment speed is slow, and current Chinese medicine material is mostly artificial kind
It plants, unsatisfactory curative effect;The health care products such as good propolis, the royal jelly sold in the market, it is expensive, and contain certain sugar, it is not suitable for
Diabetes patient's long-term consumption.The insulin of injection mostly contains hormone, can generate adverse effect to human body." megavitamin
D3 supplements influence to diabetes rat glycolipid metabolism and DNA damage " in a text, it is noted that large dosage of vitamin D 3 can drop
The value of fasting blood glucose, but do not have significant difference, and large dosage of vitamin D 3 can be to causing Serum Calcium Phosphorus unbalance and rouge
The side effects such as matter metabolic disorder;In " influence of the vitamin A bound insulin intervention to STZ blood glucose in diabetic rats " text, mention
Blood glucose value can be reduced to replenishing vitamins A, but does not have significant difference.It is got over by the research of the Dietary frequency of target spot of intestinal flora
Come more, is also increasingly become research hotspot by the concern of scientists.Such as Chinese Tiny ecosystem magazine 2 months 2018 the 30th
Rolled up for the 2nd phase the mechanism of action and phase that probiotics prevention blood glucose is referred in " research achievement of the probiotics in Regulation of blood glucose " text
Experimental data is closed, but has been only referred to viable bacteria, is not related to probiotics fermention object but, probiotics is influenced by temperature and oxygen, is used
Property is restricted.Probiotics fermention object powder is sterilising prods, is not influenced by temperature and oxygen, and application range is wider, more passes through
Ji.
Summary of the invention
The object of the present invention is to provide a kind of hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its answer
With to meet the needs of people.And this composition also has intestinal health, raising immune, treats the effect of canker sore.
The hypoglycemic vitamin and probiotics fermention product powder alimentation composition, the component including parts by weight:
10 parts~15 parts of vitamin mixed powder
1~5 part of probiotics fermention object powder
0.5 part~70 parts of sugar alcohol
Preferably, further includes:
59~15 parts of disintegrating agent
0.4~10 part of lubricant
The vitamin mixed powder includes vitamin A, vitamin D, vitamin B5 and vitamin B12, weight ratio are as follows:
Vitamin A: vitamin D: vitamin B5: vitamin B12=1:0.001~0.1:5~25:0.0008~0.01;
Preferably, vitamin A: vitamin D: vitamin B5: vitamin B12=vitamin A: vitamine D3: vitamin B5:
Vitamin B12=1:0.01~0.03:10~15:0.003~0.004
The vitamin A includes one or more of retinol acetate and beta carotene, and preferably acetic acid view is yellow
The mixture of ester and beta carotene, weight ratio are retinol acetate: beta carotene=1:1~4:1
The vitamin D includes one or more of calciferol and vitamine D3;
The vitamin B5 is calcium pantothenate;
The probiotics fermention object powder be lactobacillus plantarum, Lactobacillus salivarius, bifidobacterium longum, lactobacillus acidophilus hair
Ferment product, containing lactic acid, victory peptide, mycelial polysaccharides, hydrogen peroxide, ablastins, biacetyl flavonoids, vitamin and minerals etc.,
The product of Anhui Jin Qiao company offer is provided;
The sugar alcohol is selected from one of sweet and sour sweet dew, antierythrite, D-sorbite, xylitol or a variety of;
The disintegrating agent be selected from cornstarch, sodium carboxymethyl starch, croscarmellose sodium, crospovidone and
One of gas-producing disintegrant is a variety of;
The lubricant is selected from magnesium stearate, fumaric acid odium stearate, macrogol, leucine, sucrose ester, rich horse
One of sour sodium is a variety of;
The preparation method of hypoglycemic vitamin and probiotics fermention product powder alimentation composition of the invention is conventional
Physical mixing processes after mixing, can be used method well known in the art, be prepared into tablet.
Test proves that hypoglycemic vitamin of the invention and probiotics fermention product powder alimentation composition have blood glucose
Significant reduction effect, can be used for preparing health-caring product capable of reducing blood sugar;
The invention further relates to a kind of health-caring product capable of reducing blood sugar, including a effective amount of hypoglycemic vitamin and benefit of health care
Raw bacterium fermentation material powder alimentation composition and pharmaceutically acceptable carrier, carrier disintegrating agent as mentioned or lubricant
One or more of.
The beneficial effects of the present invention are: the present invention is safe and healthy, the present invention can be inhaled in Orally disintegrating by mucous membrane of mouth
Take in into blood, head cross answer it is small, it is rapid-action, also reduce destruction of the gastric acid to the alimentation composition, improve bioavilability.
The composition, which also has, prevents and treats dry and astringent weak ophthalmodynia, dark adaptation, eye-blurred, photophobia, eyes, blink, myopia or view
The eye diseases such as film macular degeneration also have anti-aging, anti-inflammatory, the effect for improving immunity.
Specific embodiment
Embodiment 1
Formula:
Wherein: the vitamin mixed powder includes vitamin A, vitamin D, vitamin B5 and vitamin B12, weight ratio
Are as follows:
Vitamin A: vitamine D3: vitamin B5: vitamin B12=1:0.01:10:0.004;
The vitamin A is the mixture of retinol acetate and beta carotene, weight ratio are as follows:
Retinol acetate: beta carotene=2:1
Production method: it after each component is mixed, adopts with method known in this field, is prepared into tablet.
Control group 1
In vitamin mixed powder, vitamin A: vitamine D3: vitamin B5: vitamin B12=1:0.01:10:0.004,
Weight ratio;
Production method: it is adopted after each component is mixed and is prepared into tablet with method known in this field.
Control group 2
Production method: it is adopted after each component is mixed and is prepared into tablet with method known in this field.
Embodiment 2
Vitamin A: vitamine D3: vitamin B5: vitamin B12=1:0.03:15:0.003, weight ratio;Sugar alcohol: sweet dew
Sugar alcohol: D-sorbite=9:1, weight ratio;
Vitamin A in mixed powder is the mixture of retinol acetate and beta carotene, retinol acetate: β-carrot
Element=3:1
Production method: it adopts with method known in this field, is prepared into tablet;
Control group 3
Vitamin A: vitamine D3: vitamin B5: vitamin B12=1:0.03:15:0.003
Sugar alcohol: mannitol: D-sorbite=9:1, weight ratio;
It adopts and is prepared into tablet with method known in this field.
Control group 4
Sugar alcohol: mannitol: D-sorbite=9:1, weight ratio;
It adopts and is prepared into tablet with method known in this field.
Embodiment 3
1. zoopery
(1) animal selects: selecting ICR mouse (offer of zoopery middle school, Shenyang Pharmaceutical University), between weight 18-22g.
(2) drug administration: being all made of gastric infusion, and dosage is expressed as dosage 100mg/kg weight~200mg/kg weight
(3) the drop blood of this composition hyperglycemia model and grouping: is studied using alloxan cause experimental hyperglycemia model
Sugar effect.
After ICR mouse fasting 12h, according to dosage alloxan is injected intraperitoneally in 180mg/kg, and mouse tail end takes hematometry after 5d
Blood glucose.Blood glucose value is chosen in the mouse of 11.1~24mmol/L, is grouped at random, every group 12, totally 8 groups, blood glucose value between each group
Mean value is not statistically significant (P > 0.05).
Be respectively model control group, example 1 group, 2 groups of embodiment, control 1 group, control 2 groups, control 3 groups, control 4 groups,
Melbine group;Embodiment group and the daily stomach-filling 150mg/kg of each control group.The daily stomach-filling melbine of melbine group
250mg/kg.Taking 12 mouse that alloxan is not injected intraperitoneally is Normal group;
0.5% sodium carboxymethylcellulose of Normal group and the daily stomach-filling of model control group in equal volume, embodiment group,
The product of corresponding dosage is given in stomach-filling respectively for control group and melbine group, 10mL/kg, 1 time a day continuous gavage 8 weeks.
(4) index determining: measuring every group of every daily inleting appetite of animal in experimentation, calculate every group of every mouse be averaged day into
Appetite (difference of adjacent two days every group of animal feeds/every group of number of animals, altogether record 8 weeks it is for statistical analysis);Mouse fasting is not
After prohibiting 6~8h of water, cuts tail point and blood blood glucose meter is taken to measure fasting blood-glucose.At administration 8 week, mouse weight is weighed, eyeball is plucked and takes blood,
After the static 1h of room temperature, it is centrifugated serum, Elisa kit method measures serum insulin level.
(5) data are analyzed: each group of data is indicated with mean+SD (x ± s), carries out single factor test using SPSS software
Variance analysis is compared between multiple groups two-by-two using LSD method, is that difference has conspicuousness with P < 0.05.
(5) experimental result
1 embodiment of table is averaged to mouse and day uses up appetite and changes of weight
Group | Quantity | Average daily inleting appetite (g) | Weight (g) after 8 weeks |
Normal group | 12 | 3.24±0.60 | 26.81±2.29 |
Model control group | 12 | 4.44±0.78** | 56.78±3.40** |
Example 1 group | 12 | 4.57±0.72** | 63.32±3.36**# |
Compare 1 group | 12 | 4.37±0.80** | 56.67±1.96** |
Compare 2 groups | 12 | 4.45±1.01** | 55.98±2.87** |
2 groups of embodiment | 12 | 4.50±0.73** | 65.28±3.94**# |
Compare 3 groups | 12 | 4.46±0.82** | 53.90±2.48** |
Compare 4 groups | 12 | 4.47±0.74** | 55.57±2.90** |
Melbine group | 12 | 4.35±0.92** | 62.26±4.70**# |
Note: compared with Normal group, * * P < 0.01;Compared with model group, #P < 0.05;
2 embodiment of table takes the influence to mouse fasting blood-glucose in 8 weeks
Note: compared with Normal group, * P < 0.05, * * P < 0.01;Compared with model group, #P < 0.05, ##P <
0.01;
Influence of 3 embodiment of table to mice serum insulin level
Group | Quantity | Serum insulin (ng/mL) |
Normal group | 12 | 0.90±1.20 |
Model control group | 12 | 54.21±39.51** |
Example 1 group | 12 | 57.04±28.58** |
Compare 1 group | 12 | 84.29±29.47**# |
Compare 2 groups | 12 | 87.78±37.43**# |
2 groups of embodiment | 12 | 57.67±28.90** |
Compare 3 groups | 12 | 89.33±29.05**# |
Compare 4 groups | 12 | 88.65±37.81**# |
Melbine group | 12 | 66.54±59.00** |
Note: compared with Normal group, * * P < 0.01;Compared with model group, #P < 0.05;
Know from table 1, table 2, table 3, embodiment 1 and 2 effect of embodiment are close with melbine group, are better than each control group;
Clinical observation;
1. Lee, female, 69 years old, three is high for many years, and blood glucose is unstable always, by taking embodiment 1 45 days, glucostasis,
Frequent micturition, glucose in urine, thirsty symptom obviously disappear, and body is obviously comfortable.Former AC Sugar is 13mmol/L or so, and blood glucose is steady after meal
Determine 18.0mmol/L or so, existing AC Sugar stablizes 8mmol/L or so, after meal glucostasis 11mmol/L or so.It takes 60 days
AC Sugar stablizes 7.5mmol/L or so afterwards, after meal glucostasis 10.5mmol/L or so.In the process, patient feeds back immunity
It gets a promotion.
2. Mr. Wang, male, 65 years old, many years diabetes, by taking embodiment 2 45 days, glucostasis, three-many-one-little symptom
It is basic to disappear.Former AC Sugar is 12.5mmol/L or so, after meal glucostasis 17.0mmol/L or so, and existing AC Sugar is stablized
7.0mmol/L or so, after meal glucostasis 9.5mmol/L or so;After taking 60 days, AC Sugar stablizes 6.5mmol/L or so,
Glucostasis 9.0mmol/L or so after meal.In the process, patient's physical strength is promoted, and is moved not easy to fatigue.
Claims (10)
1. hypoglycemic vitamin and probiotics fermention object powder alimentation composition, which is characterized in that the component including parts by weight:
10 parts~15 parts of vitamin mixed powder
1~5 part of probiotics fermention object powder
0.5 part~70 parts of sugar alcohol.
2. hypoglycemic vitamin according to claim 1 and probiotics fermention object powder alimentation composition, which is characterized in that
Further include:
59~15 parts of disintegrating agent
0.4~10 part of lubricant.
3. hypoglycemic vitamin according to claim 1 and probiotics fermention object powder alimentation composition, which is characterized in that
The vitamin mixed powder includes vitamin A, vitamin D, vitamin B5 and vitamin B12, weight ratio are as follows:
Vitamin A: vitamin D: vitamin B5: vitamin B12=1:0.001~0.1:5~25:0.0008~0.01.
4. hypoglycemic vitamin according to claim 1 and probiotics fermention object powder alimentation composition, which is characterized in that
Vitamin A: vitamin D: vitamin B5: vitamin B12=vitamin A: vitamine D3: vitamin B5: vitamin B12=1:
0.01~0.03:10~15:0.003~0.004.
5. hypoglycemic vitamin according to any one of claims 1 to 4 and probiotics fermention object powder alimentation composition,
It is characterized in that, the vitamin A includes one or more of retinol acetate and beta carotene.
6. hypoglycemic vitamin according to claim 5 and probiotics fermention object powder alimentation composition, which is characterized in that
The vitamin A is the mixture of retinol acetate and beta carotene, and weight ratio is retinol acetate: beta carotene=
1:1~4:1.
7. hypoglycemic vitamin according to any one of claims 1 to 4 and probiotics fermention object powder alimentation composition,
It is characterized in that, the vitamin D includes one or more of calciferol and vitamine D3.
8. hypoglycemic vitamin according to any one of claims 1 to 4 and probiotics fermention object powder alimentation composition,
It is characterized in that, the vitamin B5 is calcium pantothenate.
9. described in any item hypoglycemic vitamins and probiotics fermention object powder alimentation composition exist according to claim 1~8
Prepare the application in health-caring product capable of reducing blood sugar.
10. a kind of health-caring product capable of reducing blood sugar, raw including a effective amount of hypoglycemic dimension according to any one of claims 1 to 8 of health care
Element and probiotics fermention object powder alimentation composition and pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910708111.0A CN110384240A (en) | 2019-08-01 | 2019-08-01 | Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910708111.0A CN110384240A (en) | 2019-08-01 | 2019-08-01 | Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110384240A true CN110384240A (en) | 2019-10-29 |
Family
ID=68288272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910708111.0A Pending CN110384240A (en) | 2019-08-01 | 2019-08-01 | Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110384240A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111150059A (en) * | 2020-01-19 | 2020-05-15 | 西倍健生物科技(深圳)有限公司 | Special probiotic bacterium composition for women and application thereof |
CN114376135A (en) * | 2020-10-16 | 2022-04-22 | 杭州创盈生物科技有限公司 | Intestine-moistening bowel-relaxing probiotic composition solid beverage and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008039531A1 (en) * | 2006-09-27 | 2008-04-03 | Little Calumet Holdings, Llc | Probiotic oral dosage forms |
CN106036911A (en) * | 2016-06-21 | 2016-10-26 | 广州宇晟生物科技有限公司 | Probiotics diet composition and functional food for regulating blood glucose level |
CN106039050A (en) * | 2016-05-26 | 2016-10-26 | 三株福尔制药有限公司 | Composition of probiotic-fermented corn stigma as well as preparation method and application of composition |
CN107927794A (en) * | 2017-12-20 | 2018-04-20 | 北京康比特体育科技股份有限公司 | A kind of probiotics functional food composition and preparation method thereof |
US20180125901A1 (en) * | 2016-11-03 | 2018-05-10 | Cell Biotech Co., Ltd. | Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease |
-
2019
- 2019-08-01 CN CN201910708111.0A patent/CN110384240A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008039531A1 (en) * | 2006-09-27 | 2008-04-03 | Little Calumet Holdings, Llc | Probiotic oral dosage forms |
CN106039050A (en) * | 2016-05-26 | 2016-10-26 | 三株福尔制药有限公司 | Composition of probiotic-fermented corn stigma as well as preparation method and application of composition |
CN106036911A (en) * | 2016-06-21 | 2016-10-26 | 广州宇晟生物科技有限公司 | Probiotics diet composition and functional food for regulating blood glucose level |
US20180125901A1 (en) * | 2016-11-03 | 2018-05-10 | Cell Biotech Co., Ltd. | Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease |
CN107927794A (en) * | 2017-12-20 | 2018-04-20 | 北京康比特体育科技股份有限公司 | A kind of probiotics functional food composition and preparation method thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111150059A (en) * | 2020-01-19 | 2020-05-15 | 西倍健生物科技(深圳)有限公司 | Special probiotic bacterium composition for women and application thereof |
CN114376135A (en) * | 2020-10-16 | 2022-04-22 | 杭州创盈生物科技有限公司 | Intestine-moistening bowel-relaxing probiotic composition solid beverage and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103238897B (en) | Composite plant solid drink suitable for diabetic patients | |
CN102757508B (en) | A kind of Radix Ophiopogonis polysaccharide extract has the application in the foodstuff additive of weight losing function, healthcare products or medicine in preparation | |
CN104026446A (en) | Nutritional meal replacement powder suitable for crowd with hyperglycemia and preparation method thereof | |
WO2018145664A1 (en) | Anti-fatigue composition for use in improving endurance performance | |
WO2018090983A9 (en) | Saponin compound for improving intestinal microflora, preparation method and use thereof | |
CN113274481B (en) | Composition for regulating blood sugar and preparation method and application thereof | |
CN112263669A (en) | Oligopeptide traditional Chinese medicine probiotic compound for relieving hyperuricemia | |
KR20170028486A (en) | Composition for Preventing, Treating or Improving Menopausal Syndrome comprising Sparassis crispa Wulf.: Fr. and Lactic Acid Bacteria as Active Ingredient | |
CN114343183A (en) | Polysaccharide and probiotic composition for regulating and controlling intestinal anti-constipation activity | |
TWI627959B (en) | Use of lactobacillus reuteri gmnl-263 for manufacturing composition for increasing expression of ldl-r and cyp7a1 in liver in high-fat diet individual | |
CN110384240A (en) | Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application | |
CN111870609A (en) | Intestinal flora regulator and application thereof | |
CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
CN106174484A (en) | There is the enzyme composition of cough and asthma relieving efficacy, effervescent granule and preparation method | |
CN107455739A (en) | A kind of three high drop health care nutrition powder | |
CN102631466A (en) | Health care product for regulating blood lipid and preparation method thereof | |
CN109045070A (en) | A kind of composition for preventing and treating non-alcoholic fatty liver disease | |
CN108653298A (en) | Monosaccharide composition, pharmaceutical preparation and its application | |
CN111281902A (en) | Application of lithocarpus litseifolius or active extract thereof | |
CN102499366A (en) | Health-care food for adjusting blood fat and preventing fatigue | |
CN102225082B (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
CN103721074B (en) | Pharmaceutical composition and preparation method and application thereof | |
TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver | |
CN115177658B (en) | Composition for reducing blood sugar | |
CN112336754B (en) | Application of cladosporium compound microbial inoculum in preparation of medicines for treating metabolic diseases and culture method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191029 |
|
RJ01 | Rejection of invention patent application after publication |